EUGENE, Ore. – The FDA has approved the first treatment for metastatic breast cancer for patients who have a BRCA gene mutation.
This is the same class of drugs that’s being used to treat advanced ovarian cancer.
Researchers said in clinical trials, the tumors of patients who took the drug didn’t have significant growth for seven months compared to four months for patients who just underwent chemotherapy.
The FDA also approved a blood test to detect BRCA mutations in patients with breast cancer.
The National Cancer Institute estimates more than 252,000 women will be diagnosed with breast cancer this year.